Empowering innovative science and transformativetherapeutics

We are a leading life sciences investor financing highly innovative companies worldwide.

We provide biotech ventures with the resources to develop novel therapies for indications with high unmet medical needs.

We invest in companies that will have a positive impact on patients and society.

Latest:
exit

22.11.2021

Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology

expertise

A diverse and
experienced team
driving the future
of health

The scientific, financial and entrepreneurial
expertise of our international team has proven
instrumental to the development of many thriving
biotech ventures.

We are united by our commitment to achieving
success for new, promising companies.

    perform

    Global outlook
    Proven performance

    >€400M

    Assets under
    management

    34

    Invested
    companies

    14

    Products brought
    to market

    >40

    Products at
    clinical stage

    breakthrough

    Backing the
    breakthroughs
    of tomorrow

    Our portfolio features an exciting mix of biotech
    companies located across Europe and the United
    States, all of which have a high potential to make
    a meaningful impact.

    latest

    Dutch med-tech innovator Xeltis lands €15 million European financing from EIB

    Xeltis will use the funding to accelerate the clinical programmes of three restorative devices that can substantially impact cardiovascular

    Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology

    Purchase price includes an upfront payment of EUR 205 million, precommercial milestones for up to EUR 170 million and progressive commercial milestones.

    Kala Pharmaceuticals Acquires Combangio, Expanding its Pipeline with a Clinical-Stage Novel Biologic for the Treatment of Persistent Corneal Epithelial Defect (PCED) and other Rare Ocular Surface Diseases

    Today’s acquisition marks a pivotal moment for Kala and a meaningful acceleration toward our goal of strengthening Kala’s pipeline for the treatment of front and back of the eye diseases,

    Aura Biosciences Presents Final Phase 1b/2 Data for its first Virus-Like Drug Conjugate, AU-011, in Patients with Choroidal Melanoma at the American Academy of Ophthalmology 2021 Annual Meeting

    AU-011 may offer patients a safe, effective first-line therapy for early-stage disease that preserves vision.

    AM-Pharma Appoints Alexander Bastian as Vice President Value & Market Access

    His responsibilities include ensuring broad patient access to ilofotase alfa, AM-Pharma’s drug candidate for the treatment of sepsis-associated acute kidney injury, currently in Phase III clinical development.